Post Marketing Pharmacovigilance Medical Information Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Post-marketing pharmacovigilance and medical information services represent a critical function within the global pharmaceutical value chain, ensuring ongoing drug safety surveillance, adverse event processing, regulatory compliance, and dissemination of evidence-based product information to healthcare stakeholders. The combined market reached approximately $14.91 billion in 2026, growing at a 6.5% CAGR from the prior year, and forms a substantial segment of the broader healthcare and pharmaceutical industry ecosystem valued in the trillions of dollars globally. This sector bridges regulatory requirements and clinical knowledge management, operating across the full lifecycle of marketed medicines from conventional small-molecule generics to complex biologics and novel gene and cell therapies.

• •The pharmacovigilance market alone is valued between $10.36 billion and $11.84 billion in 2025, with projections reaching $22.25 billion to $24.76 billion by 2030-2034, driven by escalating post-approval surveillance obligations.
• •The distinct medical information market segment was estimated at $2.98 billion to $3.45 billion in 2024 and is forecast to grow to between $6.04 billion and $7.0 billion by 2034.
• •Global pharmaceutical sales are projected to reach approximately $3.2 trillion by 2035, underpinning the long-term demand base for post-marketing safety services across all therapeutic categories.

The primary engine of market growth is the relentless expansion of the global pharmaceutical product landscape, with annual spending growth holding steady at a 5-8% CAGR and projected to reach $2.4 trillion by 2029, particularly in immunology, oncology, endocrinology, and obesity treatments. The rising complexity and volume of biologics and biosimilars in development and commercialization demand substantially more intensive safety monitoring infrastructure compared to traditional small-molecule portfolios. Stringent and continuously evolving regulatory frameworks across the United States, European Union, Japan, and emerging markets mandate comprehensive adverse event collection, signal detection, periodic safety update reports, and proactive medical information dissemination to healthcare providers and patients.

• •Biologics and specialty drug classes require more granular post-marketing surveillance due to complex mechanisms of action, targeted patient populations, and elevated safety signal profiles.
• •Regulatory agencies in key markets have progressively tightened pharmacovigilance reporting timelines, data quality standards, and risk management plan requirements, increasing the operational workload for marketing authorization holders.
• •The proliferation of real-world evidence and digital health data sources, combined with growing patient and physician expectations for timely safety information, is expanding the scope and frequency of medical information interactions.

The market is commonly segmented across service type, encompassing safety case processing, signal detection and management, risk management, regulatory reporting, and medical information inquiry handling. Geographically, North America and Europe have historically represented the largest regional markets, anchored by mature regulatory frameworks, high pharmaceutical R&D intensity, and well-established pharmacovigilance infrastructure. The Asia-Pacific region is emerging as the fastest-growing segment, driven by expanding domestic pharmaceutical manufacturing capacity, rising clinical trial activity, and the harmonization of pharmacovigilance standards across key markets including Japan, China, and India.

• •North America commands the largest regional share due to FDA reporting mandates, a high density of multinational pharmaceutical headquarters, and outsourced PV service consumption.
• •Europe maintains a significant position underpinned by the EU Pharmacovigilance System Master File requirements and the centralized EMA adverse reaction database.
• •Asia-Pacific is experiencing the most rapid expansion as regional regulatory agencies align with ICH guidelines and domestic drug markets mature across emerging economies.

Who are the notable companies in the industry?

The market exhibits a moderately consolidated competitive structure dominated by large, diversified contract research organizations and specialized service providers that offer integrated pharmacovigilance platforms spanning case intake, processing, safety database management, signal detection, and medical information query handling. A secondary tier of smaller, niche operators focuses on specific service lines such as literature screening, regulatory submission support, or medical writing, creating a bifurcated supplier ecosystem alongside vertically integrated players capable of delivering end-to-end safety and medical affairs outsourcing. IQVIA Inc. and Parexel International Corporation operate as established global contract research providers with extensive pharmacovigilance capabilities supporting drug safety monitoring. ICON plc and Syneos Health offer integrated clinical development and post-marketing safety services. Laboratory Corporation of America Holdings contributes laboratory and diagnostic data relevant to adverse event tracking, while Accenture plc and Cognizant Technology Solutions Corporation provide technology-enabled consulting and digital solutions. Ergomed Group specializes in pharmacovigilance and regulatory consultancy. Regional capacity concentration remains highest in North America and Western Europe, where the majority of large-scale pharmacovigilance operations are headquartered.

• •The industry structure combines large global CROs offering comprehensive pharmacovigilance outsourcing with boutique specialty firms concentrating on discrete sub-services such as signal management, risk management plan development, or medical information call center operations.
• •Service delivery relies heavily on specialized safety database software platforms, natural language processing for literature monitoring, and increasingly on AI-enabled tools for case triage, duplicate detection, and adverse event narrative processing.
• •Capacity is heavily concentrated in North America and Western Europe, though nearshore and offshore delivery centers in India, Eastern Europe, and Latin America are expanding to serve cost-sensitive pharmaceutical and biotech clients.

What are the recent trends and outlook?

Over the forecast horizon, the post-marketing pharmacovigilance and medical information market is expected to sustain steady growth through a combination of organic demand from pharmaceutical pipeline expansion and the accelerating adoption of AI and automation technologies that reshape operational models without necessarily reducing total market spend. The convergence of real-world evidence, electronic health records, and patient-reported outcomes is broadening the data inputs that feed safety signal detection, creating new service categories within the existing market framework. Emerging regulatory expectations around transparency, patient-centric safety communication, and proactive risk minimization strategies are likely to further expand the scope of services required from market participants through the end of the decade.

• •Artificial intelligence and machine learning are being progressively embedded across the pharmacovigilance workflow for automated adverse event extraction from unstructured sources, with the potential to restructure cost dynamics over time.
• •Real-world evidence frameworks and post-authorization safety study requirements, particularly for novel therapies such as gene therapies and cell therapies, are generating new, high-value demand within the PV services market.
• •Regulatory pressure toward greater public transparency of clinical trial and safety data, alongside expanded patient-facing safety communication mandates, is broadening the mandate for medical information and pharmacovigilance functions.